



## DNDi contract extension for PharmAust subsidiary Epichem

### Zoom Webinar

**8.30am AWST/11:30am AEDT tomorrow 4 November**

You are invited to register using this link:

[https://us06web.zoom.us/webinar/register/WN\\_g81okmzKSBqPFkHJ0YfALg](https://us06web.zoom.us/webinar/register/WN_g81okmzKSBqPFkHJ0YfALg)

*Participants may submit questions during registration or during the webinar*

**3 November, 2022 – Perth, Australia:** PharmAust Limited (ASX:PAA & PAAO), a clinical-stage biotechnology company, announces that DNDi (Drugs for Neglected Diseases), a client of its contract medicinal chemistry subsidiary Epichem, has extended its contract until March 2023. The extension is expected to generate up to AUD\$32,000.

The partnership will cease in March 2023 due to development work reaching a new phase and changes in DNDi program funding.

As PharmAust progresses with clinical stage development and commercialisation of monepantel (MPL), it is expected that any short-term spare capacity at Epichem will be taken up by PharmAust with overall cost savings.

Over 14 years Epichem has actively contributed to the DNDi vision: expanding access to simple, safe, effective tests and treatments especially for neglected patients.

Epichem's General Manager Fiona Milner said "DNDi has consistently applauded the commitment, excellence and quality of research provided by the Epichem team. In the contract medicinal chemistry business new contracts are secured and existing contracts end at some stage for a variety of reasons including funding.

"Our team has enjoyed working and partnering with DNDi for this long time and wish DNDi well for the future."

This ASX release has been approved for release by the Board of Directors.

### Enquiries:

**Anusha Aubert**  
Investor Relations  
[anusha.aubert@epichem.com.au](mailto:anusha.aubert@epichem.com.au)

**P +61 (8) 9202 6814**  
**F +61 (8) 9467 6111**  
**W [www.pharmaust.com](http://www.pharmaust.com)**  
**T @PharmAust**

### **About PharmAust Limited:**

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company which generated \$3.4 million in sales of goods & services in FY 2022.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.

### **About Epichem Pty Ltd:**

Epichem is a wholly owned subsidiary of the ASX listed company PharmAust Limited. Located in Technology Park, Western Australia, Epichem has been delivering products and services in synthetic and medicinal chemistry to the global drug discovery and pharmaceutical industries in over 40 countries worldwide for over 18 years.

Epichem has purpose-built, state-of-the-art laboratories and has world class equipment and expertise in synthetic and medicinal chemistry to support drug discovery projects, and for the cost-effective synthesis of drug analogue libraries and intermediates. It also has a rapidly growing catalogue of pharmaceutical reference standards.

Epichem also specialises in Custom Synthesis, Analytical Chemistry and Materials Science. Epichem is the winner of the WA Industry Export Award 2021 for International Health, an award also won in 2019, 2018 and 2017, the 2020 Inspiring Story of Celebrating Remarkable Resilience Nomination for WA for the Australian Export and Investment Awards and the 2021 and 2020 GHP Biotechnology Award winner for Most Innovative Chemistry Service Provider – Australia and Best in Organic Chemistry Solutions. Epichem has been inducted into the WA Export Hall of Fame.



*Australia's Leading Provider of Synthetic and Organic Chemistry*